title: The NC1 domain of type XIX collagen inhibits in vivo melanoma growth.
abstract: Type XIX collagen is a minor collagen that localizes to basement membrane zones, together with types IV, XV, and XVIII collagens. Because several NC1 COOH-terminal domains of other chains from basement membrane collagens were reported to exhibit antitumor activity, we decided to study the effects of the NC1(XIX) collagen domain on tumor progression using an experimental in vivo model of mouse melanoma. We observed a 70% reduction in tumor volume in NC1(XIX)-treated mice compared with the corresponding controls. Histologic examination of the tumors showed a strong decrease in tumor vascularization in treated mice. In vitro, NC1(XIX) inhibited the migrating capacity of tumor cells and their capacity to invade Matrigel. It also inhibited the capacity of human microvascular endothelial cells to form pseudotubes in Matrigel. This effect was accompanied by a strong inhibition of membrane type-1 matrix metalloproteinase (matrix metalloproteinase-14) and vascular endothelial growth factor expression. Collectively, our data indicate that the NC1 domain of type XIX collagen exerts antitumor activity. This effect is mediated by a strong inhibition of the invasive capacities of tumor cells and antiangiogenic effects. NC1(XIX) should now be considered as a new member of the basement membrane collagen-derived matrikine family with antitumor and antiangiogenic activity.
authors.affiliation: Laboratoire de Biochimie Médicale et Biologie Moléculaire, Faculté de Medecine, CNRS-UMR 6198, Institut Fédératif de Recherche 53 Biomolecules, Université de Reims Champagne-Ardenne, 51 rue Cognacq Jay, F-51095 Reims Cedex, France. lramont@chu-reims.fr
authors.forename: Laurent
authors.initials: L
authors.lastname: Ramont
authors.forename: Sylvie
authors.initials: S
authors.lastname: Brassart-Pasco
authors.forename: Jessica
authors.initials: J
authors.lastname: Thevenard
authors.forename: Aurélie
authors.initials: A
authors.lastname: Deshorgue
authors.forename: Lydie
authors.initials: L
authors.lastname: Venteo
authors.forename: Jean Yves
authors.initials: JY
authors.lastname: Laronze
authors.forename: Michel
authors.initials: M
authors.lastname: Pluot
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Monboisse
authors.forename: François-Xavier
authors.initials: FX
authors.lastname: Maquart
mesh_terms: D000818:Animals; D017209:Apoptosis; D001485:Basement Membrane / Q000378:metabolism; D015153:Blotting, Western; D002448:Cell Adhesion; D049109:Cell Proliferation; D003094:Collagen / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000517:prevention & control / Q000556:secondary; D053511:Matrix Metalloproteinase 14 / Q000378:metabolism; D008545:Melanoma / Q000098:blood supply / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010446:Peptide Fragments / Q000378:metabolism; D012878:Skin Neoplasms / Q000098:blood supply / Q000473:pathology / Q000517:prevention & control; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D010446:Peptide Fragments; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D003094:Collagen; C507086:MMP14 protein, human; D053511:Matrix Metalloproteinase 14